

Disclosures

Personal Commercial (29)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Anylam Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AnaCardio	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Applied Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Biopeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol Myers Squibb	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
Clinician Scientist Award (National Medical Research Council of Singapore)	Research/Research Grants ‡ Heart Failure Screening in Primary Care Using Digital Tools	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Corteria	Consultant Fees/Honoraria	None (\$0)	
CPC Clinical Research	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	
Eli Lilly	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Impulse Dynamics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Intellia Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Janssen Research & Development	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Medscape/WebMD	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk	Research/Research Grants ‡ Clinical, imaging and biomarker data exploration in HFpEF patients from ATTRaCT cohort(s)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Quidel Corporation	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
Radcliffe	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Roche	Research/Research Grants ‡ Asian Diabetes Outcomes Prevention Trial	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Us2.ai	Other - Co-founder; Non-executive Director	None (\$0)	Noninvasive Imaging
Us2.ai	Consultant Fees/Honoraria	Significant (>= \$5,000)	Noninvasive Imaging
<i>Spouse/Domestic Partner/Immediate Household Member</i>			
Us2.ai	Other - Co-founder; CEO	Significant (>= \$5,000)	Noninvasive Imaging

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/2/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/2/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/2/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.